NF1 and neoplasm: Our previous preclinical modeling suggested that efficient RAS activation in ER+ NF1-depleted breast cancers can promote tumor cell survival when ER signaling is blocked by fulvestrant, and the consequent fulvestrant resistance can be inhibited by binimetinib (9).